{"slideshow_credits": null, "snippet": "The critical shortage of generic drugs continues unabated.", "abstract": "Op-Ed article by industry experts Margaret Clapp, Michael A Rie and Phillip L Zweig warns a critical shortage of lifesaving generic drugs has persisted unabated one year after Pres Obama signed law meant to end it; calls on Obama administration and lawmakers to end protections for purchasing organizations that have colluded to suppress free-market competition in generic market.", "section_name": "Opinion", "print_page": "25", "document_type": "article", "byline": {"person": [{"firstname": "Margaret", "role": "reported", "lastname": "CLAPP", "rank": 1, "organization": ""}, {"lastname": "RIE", "rank": 2, "firstname": "Michael", "role": "reported", "organization": "", "middlename": "A."}, {"lastname": "ZWEIG", "rank": 3, "firstname": "Phillip", "role": "reported", "organization": "", "middlename": "L."}], "original": "By MARGARET CLAPP, MICHAEL A. RIE and PHILLIP L. ZWEIG", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/09/03/opinion/how-a-cabal-keeps-generics-scarce.html", "lead_paragraph": "The critical shortage of generic drugs continues unabated.", "headline": {"main": "How a Cabal Keeps Generics Scarce", "print_headline": "How a Cabal Keeps Generics Scarce", "content_kicker": "Op-Ed Contributors", "kicker": "Op-Ed Contributors"}, "_id": "5225353d38f0d8740ac9d4e2", "word_count": "720", "multimedia": [{"height": 126, "url": "images/2013/09/03/opinion/0903OPEDstafford/0903OPEDstafford-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2013/09/03/opinion/0903OPEDstafford/0903OPEDstafford-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 933, "url": "images/2013/09/03/opinion/0903OPEDstafford/0903OPEDstafford-articleLarge.jpg", "legacy": {"xlarge": "images/2013/09/03/opinion/0903OPEDstafford/0903OPEDstafford-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "933"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/09/03/opinion/0903OPEDstafford/0903OPEDstafford-thumbStandard.jpg", "legacy": {"thumbnail": "images/2013/09/03/opinion/0903OPEDstafford/0903OPEDstafford-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2013-09-03T00:00:00Z", "source": "The New York Times", "news_desk": "OpEd", "keywords": [{"value": "Food and Drug Administration", "name": "organizations", "is_major": "N", "rank": "5"}, {"value": "Shortages", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Generic Brands and Products", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Medicine and Health", "name": "subject", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "Op-Ed"}